U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C23H23ClN6O2
Molecular Weight 450.9215
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SUVOREXANT

SMILES

Cc1ccc(c(c1)C(=O)N2CCN(CC[C@@]2([H])C)c3nc4cc(ccc4o3)Cl)-n5nccn5

InChI

InChIKey=JYTNQNCOQXFQPK-MRXNPFEDSA-N
InChI=1S/C23H23ClN6O2/c1-15-3-5-20(30-25-8-9-26-30)18(13-15)22(31)29-12-11-28(10-7-16(29)2)23-27-19-14-17(24)4-6-21(19)32-23/h3-6,8-9,13-14,16H,7,10-12H2,1-2H3/t16-/m1/s1

HIDE SMILES / InChI

Molecular Formula C23H23ClN6O2
Molecular Weight 450.9215
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204569s001lbl.pdf; http://www.ncbi.nlm.nih.gov/pubmed/?term=24102345

Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R. It has been approved for the treatment of insomnia. The mechanism by which suvorexant exerts its therapeutic effect in insomnia is presumed to be through antagonism of orexin receptors. The orexin neuropeptide signaling system is a central promoter of wakefulness. Blocking the binding of wake-promoting neuropeptides orexin A and orexin B to receptors OX1R and OX2R is thought to suppress wake drive.

Originator

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: O43614
Gene ID: 3062
Gene Symbol: HCRTR2
Target Organism: Homo sapiens (Human)
0.550000000000000044 nM [Ki]
Target ID: O43613
Gene ID: 3061
Gene Symbol: HCRTR1
Target Organism: Homo sapiens (Human)
0.349999999999999978 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
BELSOMRA

Approved Use

Indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.

Launch Date

1407888000000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.08 μM
40 mg 1 times / day steady-state, oral
dose: 40 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.329 μM
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.425 μM
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.488 μM
80 mg 1 times / day steady-state, oral
dose: 80 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2.085 μM
100 mg 1 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
0.356 μM
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
0.414 μM
10 mg 1 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
0.572 μM
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
0.574 μM
20 mg 1 times / day steady-state, oral
dose: 20 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
0.802 μM
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
0.854 uM
20 mg single, oral
dose: 20 mg
route of administration: oral
experiment type: single
co-administered:
SUVOREXANT plasma
Homo sapiens
population: healthy
age:
sex:
food status: Fasted
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
10.64 μM × h
40 mg 1 times / day steady-state, oral
dose: 40 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
11.48 μM × h
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
18.1 μM × h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
18.32 μM × h
80 mg 1 times / day steady-state, oral
dose: 80 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
27.62 μM × h
100 mg 1 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
3.43 μM × h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
4.36 μM × h
10 mg 1 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
5.03 μM × h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
6.08 μM × h
20 mg 1 times / day steady-state, oral
dose: 20 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
8.53 μM × h
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
9.4 h
40 mg 1 times / day steady-state, oral
dose: 40 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
10 h
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
12.6 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
11.2 h
80 mg 1 times / day steady-state, oral
dose: 80 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
14.5 h
100 mg 1 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
7.7 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
8.1 h
10 mg 1 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
8.4 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
9.2 h
20 mg 1 times / day steady-state, oral
dose: 20 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
8.6 h
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
12 h
SUVOREXANT plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
SUVOREXANT plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
100 mg 1 times / day steady, oral
Highest studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
healthy, 34.3 years(range: 19–45 years)
Health Status: healthy
Age Group: 34.3 years(range: 19–45 years)
Sex: M+F
Sources:
Other AEs: Somnolence, Fatigue...
Other AEs:
Somnolence (67%)
Fatigue (83%)
Insomnia (17%)
Dizziness (33%)
Phlebitis (33%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Insomnia 17%
100 mg 1 times / day steady, oral
Highest studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
healthy, 34.3 years(range: 19–45 years)
Health Status: healthy
Age Group: 34.3 years(range: 19–45 years)
Sex: M+F
Sources:
Dizziness 33%
100 mg 1 times / day steady, oral
Highest studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
healthy, 34.3 years(range: 19–45 years)
Health Status: healthy
Age Group: 34.3 years(range: 19–45 years)
Sex: M+F
Sources:
Phlebitis 33%
100 mg 1 times / day steady, oral
Highest studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
healthy, 34.3 years(range: 19–45 years)
Health Status: healthy
Age Group: 34.3 years(range: 19–45 years)
Sex: M+F
Sources:
Somnolence 67%
100 mg 1 times / day steady, oral
Highest studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
healthy, 34.3 years(range: 19–45 years)
Health Status: healthy
Age Group: 34.3 years(range: 19–45 years)
Sex: M+F
Sources:
Fatigue 83%
100 mg 1 times / day steady, oral
Highest studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
healthy, 34.3 years(range: 19–45 years)
Health Status: healthy
Age Group: 34.3 years(range: 19–45 years)
Sex: M+F
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 5.3 uM]
no [IC50 >100 uM]
no
weak [IC50 11 uM]
weak [IC50 15 uM]
weak [IC50 15 uM]
weak [IC50 17 uM]
weak [IC50 35 uM]
weak [IC50 37 uM]
weak [IC50 39 uM]
weak [IC50 44 uM]
weak [IC50 47 uM]
weak [IC50 64 uM]
weak [IC50 74 uM]
weak
yes [IC50 1.3 uM]
yes [IC50 10 uM]
yes [IC50 4 uM]
yes [IC50 73 uM]
yes [Inhibition 15 uM]
yes [Inhibition 15 uM]
yes
yes
yes
Drug as victim
PubMed

PubMed

TitleDatePubMed
Dual orexin receptor antagonists - promising agents in the treatment of sleep disorders.
2014 Jan
Suvorexant: a novel therapy for the treatment of insomnia.
2014 Oct
Suvorexant: a dual orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia.
2015 Apr
Patents

Sample Use Guides

The recommended dose for BELSOMRA (suvorexant) is 10 mg, taken no more than once per night and within 30 minutes of going to bed, with at least 7 hours remaining before the planned time of awakening. If the 10 mg dose is well-tolerated but not effective, the dose can be increased. The maximum recommended dose of BELSOMRA is 20 mg once daily
Route of Administration: Oral
Examination of Suvorexant in radioligand binding assays using tissue from transgenic rats expressing the human OX2R found nearly full receptor occupancy (>90%) at plasma exposures of 1.1 μM.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:40:37 UTC 2021
Edited
by admin
on Fri Jun 25 21:40:37 UTC 2021
Record UNII
081L192FO9
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SUVOREXANT
DASH   INN   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
BELSOMRA COMPONENT SUVOREXANT
Brand Name English
SUVOREXANT [JAN]
Common Name English
METHANONE, ((7R)-4-(5-CHLORO-2-BENZOXAZOLYL)HEXAHYDRO-7-METHYL-1H-1,4-DIAZEPIN-1-YL)(5-METHYL-2-(2H-1,2,3-TRIAZOL-2-YL)PHENYL)-
Systematic Name English
MK4305
Code English
SUVOREXANT [USAN]
Common Name English
SUVOREXANT [INN]
Common Name English
MK-4305
Code English
SUVOREXANT [MI]
Common Name English
SUVOREXANT COMPONENT OF BELSOMRA
Brand Name English
SUVOREXANT [WHO-DD]
Common Name English
((7R)-4-(5-CHLORO-1,3-BENZOXAZOL-2-YL)-7-METHYL-1,4-DIAZEPAN-1-YL)(5-METHYL-2-(2H-1,2,3-TRIAZOL-2-YL)PHENYL)METHANONE
Systematic Name English
SUVOREXANT [ORANGE BOOK]
Common Name English
BELSOMRA
Brand Name English
SUVOREXANT [VANDF]
Common Name English
Classification Tree Code System Code
WHO-ATC N05CM19
Created by admin on Fri Jun 25 21:40:37 UTC 2021 , Edited by admin on Fri Jun 25 21:40:37 UTC 2021
DEA NO. 2223
Created by admin on Fri Jun 25 21:40:37 UTC 2021 , Edited by admin on Fri Jun 25 21:40:37 UTC 2021
NDF-RT N0000191000
Created by admin on Fri Jun 25 21:40:37 UTC 2021 , Edited by admin on Fri Jun 25 21:40:37 UTC 2021
Code System Code Type Description
EVMPD
SUB180101
Created by admin on Fri Jun 25 21:40:37 UTC 2021 , Edited by admin on Fri Jun 25 21:40:37 UTC 2021
PRIMARY
IUPHAR
2890
Created by admin on Fri Jun 25 21:40:37 UTC 2021 , Edited by admin on Fri Jun 25 21:40:37 UTC 2021
PRIMARY
ChEMBL
CHEMBL1083659
Created by admin on Fri Jun 25 21:40:37 UTC 2021 , Edited by admin on Fri Jun 25 21:40:37 UTC 2021
PRIMARY
NDF-RT
N0000185503
Created by admin on Fri Jun 25 21:40:37 UTC 2021 , Edited by admin on Fri Jun 25 21:40:37 UTC 2021
PRIMARY P-Glycoprotein Inhibitors [MoA]
RXCUI
1547099
Created by admin on Fri Jun 25 21:40:37 UTC 2021 , Edited by admin on Fri Jun 25 21:40:37 UTC 2021
PRIMARY RxNorm
NDF-RT
N0000190114
Created by admin on Fri Jun 25 21:40:37 UTC 2021 , Edited by admin on Fri Jun 25 21:40:37 UTC 2021
PRIMARY Cytochrome P450 3A Inhibitors [MoA]
FDA UNII
081L192FO9
Created by admin on Fri Jun 25 21:40:37 UTC 2021 , Edited by admin on Fri Jun 25 21:40:37 UTC 2021
PRIMARY
CAS
1030377-33-3
Created by admin on Fri Jun 25 21:40:37 UTC 2021 , Edited by admin on Fri Jun 25 21:40:37 UTC 2021
PRIMARY
INN
9435
Created by admin on Fri Jun 25 21:40:37 UTC 2021 , Edited by admin on Fri Jun 25 21:40:37 UTC 2021
PRIMARY
NDF-RT
N0000190998
Created by admin on Fri Jun 25 21:40:37 UTC 2021 , Edited by admin on Fri Jun 25 21:40:37 UTC 2021
PRIMARY Orexin Receptor Antagonists [MoA]
NCI_THESAURUS
C171858
Created by admin on Fri Jun 25 21:40:37 UTC 2021 , Edited by admin on Fri Jun 25 21:40:37 UTC 2021
PRIMARY
PUBCHEM
24965990
Created by admin on Fri Jun 25 21:40:37 UTC 2021 , Edited by admin on Fri Jun 25 21:40:37 UTC 2021
PRIMARY
MERCK INDEX
M11766
Created by admin on Fri Jun 25 21:40:37 UTC 2021 , Edited by admin on Fri Jun 25 21:40:37 UTC 2021
PRIMARY
EPA CompTox
1030377-33-3
Created by admin on Fri Jun 25 21:40:37 UTC 2021 , Edited by admin on Fri Jun 25 21:40:37 UTC 2021
PRIMARY
DRUG BANK
DB09034
Created by admin on Fri Jun 25 21:40:37 UTC 2021 , Edited by admin on Fri Jun 25 21:40:37 UTC 2021
PRIMARY
DRUG CENTRAL
4881
Created by admin on Fri Jun 25 21:40:37 UTC 2021 , Edited by admin on Fri Jun 25 21:40:37 UTC 2021
PRIMARY
WIKIPEDIA
SUVOREXANT
Created by admin on Fri Jun 25 21:40:37 UTC 2021 , Edited by admin on Fri Jun 25 21:40:37 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
TARGET -> INHIBITOR
BINDER->LIGAND
BINDING
METABOLIC ENZYME -> SUBSTRATE
MINOR
METABOLIC ENZYME -> SUBSTRATE
MAJOR
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Tmax PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC